TCT-586 Alirocumab efficacy and safety in patients with prior coronary revascularization

TCT-586 Alirocumab efficacy and safety in patients with prior coronary revascularization

Results Of 4629 total randomized patients, 2191 (47.3%) had prior revascularization; of these, >50% had history of acute MI, 53-84% were on high intensity statin therapy, mean age was 60-62 years and 71-70% were male (ranges over pooled groups). Conclusion Alirocumab resulted in significant reduc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B242-B243
Hauptverfasser: Kereiakes, Dean, Lepor, Norman, Gerber, Robert, Lee, L. Veronica, Thompson, Desmond, Gibson, C. Michael
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Lipids
Low density lipoprotein
Monoclonal antibodies
Statins
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Results Of 4629 total randomized patients, 2191 (47.3%) had prior revascularization; of these, >50% had history of acute MI, 53-84% were on high intensity statin therapy, mean age was 60-62 years and 71-70% were male (ranges over pooled groups). Conclusion Alirocumab resulted in significant reductions in LDL-C and other atherogenic lipids and was generally well-tolerated in high-risk patients with prior revascularization (PCI or CABG).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.770